Your eligible patients can save on their ZEGALOGUE prescription with the ZEGALOGUE Co-Pay Savings Card. Just download a card, and give it to your patient to bring to the pharmacy when they drop off their ZEGALOGUE prescription.
TERMS AND CONDITIONS
Patient Instructions: The ZEGALOGUE Co-Pay Savings Card Program is ONLY valid for patients with commercial (private) insurance. In order to redeem this offer, you must have a valid prescription for ZEGALOGUE and you may not be enrolled in a state or federally funded prescription benefit program, including, but not limited to, Medicare (Parts A, B, C, or D), Medicaid (including Managed Medicaid), Veterans Affairs (VA), Department of Defense (DOD), or TRICARE. You are responsible for the first $25 and the card pays the remainder per prescription, up to a maximum of 12 fills per calendar year. Follow instructions provided by your doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section of the full Terms and Conditions, including that you will not seek reimbursement for any part of the benefit received through this offer from any third-party payer, including any health savings, flexible spending, or other healthcare reimbursement account. Patients with questions about the offer should call 1-877-501-ZEGA (9342). THIS OFFER IS NOT INSURANCE. Subject to additional terms and conditions, which can be found here.
ePrescribe in your electronic medical records (EMR) system—select Careform Pharmacy or NPI 1043762750
- OR FAX a prescription to Careform Pharmacy at 1-412-774-9652
- OR CALL Zealand Pharma ConnectedCare at 1-877-501-ZEGA (9342)
Alert your patients that they’ll get a text or phone call from:
- Zealand Pharma ConnectedCare: 1-877-501-9342, or
- Amber Specialty Pharmacy: 1-888-370-1724
That’s it! Zealand Pharma ConnectedCare will handle the rest
*Must meet eligibility criteria.
IMPORTANT SAFETY INFORMATION
ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.